Sector News

Raptor Pharma (RPTP) Appoints New SVP, Gen. Counsel

July 16, 2015
Life sciences
Raptor Pharma announced the appointment of Ashley Gould, J.D. as its Senior Vice President, General Counsel and Corporate Governance. In addition, Ted Daley, Chief Business Officer, will be leaving the company at the end of September to pursue other interests.
 
“I am delighted to welcome Ashley to Raptor’s executive team,” said Julie Anne Smith, President and CEO of Raptor Pharmaceutical. “She has highly relevant expertise in biopharma spanning regulatory, quality assurance, governmental, and legal in addition to other functions. As Raptor continues to grow, I am confident she will prove an excellent strategic addition and I look forward to her counsel. Separately, I would like to thank Ted for all of the contributions he has made to Raptor’s success over the years. His involvement across all functions has been invaluable as we’ve grown into a commercial, global organization. On behalf of the Board and other members of the executive team, we wish him well in his future endeavors.”
 
Most recently Ms. Gould served as Senior Vice President, Governmental Affairs and Chief Legal and Compliance Officer for Hyperion Therapeutics. Before that, she held a number of positions of increasing responsibility at 23andMe, culminating in her appointment as Vice President, Corporate Development and Chief Legal Officer. Previously she was Vice President, Legal Affairs at CoTherix, where she worked on the company’s acquisition by Actelion, and an associate at the law firms of O’Melveny & Myers and Wilson Sonsini Goodrich & Rosati. Ms. Gould received a B.S. in Political Economy of Natural Resources from University of California, Berkeley and a J.D. from the University of San Francisco School of Law.
 
Source: Raptor

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend